| 摘要: |
| [目的] 观察加味升降散辅助治疗Ⅳ期糖尿病肾病（DKD）的临床效果。[方法] 将80例中医辨证为气虚血瘀、湿热互结的Ⅳ期DKD患者随机分成观察组和对照组，各40例。两组均予常规糖尿病教育、降糖、控压、调脂等基础治疗，观察组在对照组的基础上联用加味升降散，疗程12周。比较治疗前后两组的总有效率、24 h尿蛋白定量（24 h UP）、血肌酐（Scr）、血尿素氮（BUN）及白细胞介素-1β（IL-1β）、白细胞介素-6（IL-6）、肿瘤坏死因子-α（TNF-α）的水平。[结果] 治疗前，两组患者的基线资料、相关临床指标及炎症因子水平差异无统计学意义，具有可比性（P>0.05）；治疗后，观察组的总有效率高于对照组（P<0.05），24 h UP、Scr、BUN及IL-1β、IL-6、TNF-α水平显著低于对照组（P<0.001）且不增加患者的不良反应。[结论] 加味升降散辅助治疗Ⅳ期DKD的临床疗效显著，不仅可进一步提升患者的总有效率、减轻炎症反应、改善肾功能，并且具有良好的安全性。 |
| 关键词: 糖尿病肾病 加味升降散 临床疗效 总有效率 炎症因子 |
| DOI：10.11656/j.issn.1673-9043.2022.02.13 |
| 分类号:R587.2 |
| 基金项目:河南省科技攻关计划项目（182102311167）；河南省自然科学基金项目（2018ZY1001）。 |
|
| Clinical effect of modified Shengjiang Powder in patients with Ⅳ-stage diabetic nephropathy |
|
CHENG Liying1, ZHANG Zhu2, MA Jiwei3, WANG Qin1, LIU Haofei3, LUO Weixian4
|
|
1.Henan University of Traditional Chinese Medicine, Zhengzhou 450064, China;2.Department of Nephrology, Fuwai Huazhong Cardiovascular Hospital, Zhengzhou 451464, China;3.Department of Nephrology, the First Affiliated Hospital of Henan of Traditional Chinese Medicine, Zhengzhou 450003, China;4.Department of Traditional Chinese Medicine, Zhengzhou First People's Hospital, Zhengzhou 450000, China
|
| Abstract: |
| [Objective] To investigate the clinical efficacy of Modified Shengjiang Powder in patients with Mid-stage diabetic nephropathy(DN). [Methods] The 80 cases of mid-stage DN patients with qi deficiency,blood stasis,and damp-heat are randomly divided into observation group and control group,with 40 cases in each group. The two groups were treated with routine diabetes education,hypoglycemia,blood pressure control,lipid regulation and other basic treatments. The observation group was combined with the control group to receive Modified Shengjiang Powder for a course of 12 weeks. The total response rate,24 h urinary protein level(24 h UP),serum creatinine (Scr),urea nitrogen (BUN),interleukin-1β(IL-1β),interleukin-6(IL-6),tumor necrosis factor-α(TNF-α) were compared between the two groups before and after treatment. [Results] Before treatment,there were no statistically significant differences in baseline data,related clinical indicators and inflammatory cytokines between the two groups(P<0.05). After treatment,the total effective rate of the observation group was higher than that of the control group(P<0.05),24 h UP,Scr,BUN,IL-1β,IL-6 and TNF-α levels were significantly lower than those in control group (P<0.001) and did not increase adverse events in patients. [Conclusion] Modified Shengjiang Powder has significant clinical effects in adjuvant treatment of patients with mid-stage DN. It can not only further enhance the total effective rate of patients,reduce inflammation,improve renal function,but also has good safety. |
| Key words: diabetic kidney disease modified Shengjiang Powder clinical effects total efficiency inflammatory cytokines |
